QRG Capital Management Inc. Acquires 49,804 Shares of Pfizer Inc. $PFE

QRG Capital Management Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 5.8% in the second quarter, Holdings Channel reports. The institutional investor owned 902,308 shares of the biopharmaceutical company’s stock after acquiring an additional 49,804 shares during the quarter. QRG Capital Management Inc.’s holdings in Pfizer were worth $21,728,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the fourth quarter valued at $26,000. Keb Asset Management LLC purchased a new stake in Pfizer during the 2nd quarter worth about $26,000. HFM Investment Advisors LLC boosted its stake in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the period. Finally, Abound Financial LLC purchased a new stake in shares of Pfizer in the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $26.80 on Friday. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The company has a fifty day moving average of $25.11 and a 200-day moving average of $26.19. The company has a market capitalization of $152.77 billion, a P/E ratio of 35.27 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the business posted $0.78 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer CEO Albert Bourla purchased approximately $1 million of company stock, adding 38,000 shares. The insider purchase may signal management’s confidence that the shares are undervalued. Pfizer CEO Buys $1 Million of Stock
• Positive Sentiment: Pfizer’s second-quarter results exceeded expectations, and management modestly raised 2026 revenue guidance to $60.5 billion-$62.5 billion. Analysts also highlighted stable core operations, strength from acquired brands and recent launches, and momentum in the non-COVID business. 5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
• Positive Sentiment: Positive Phase 3 results for LITFULO in nonsegmental vitiligo strengthen Pfizer’s immunology pipeline and support the company’s effort to replace declining COVID-related revenue with newer products. Pfizer’s Higher 2026 Guidance and LITFULO Trial Results
• Positive Sentiment: Recent coverage points to growing investor interest in Pfizer’s launches, acquisitions and pipeline as potential drivers of longer-term growth, particularly from 2029 onward. Will Pfizer’s Non-COVID Portfolio Drive Its Next Phase of Growth?
• Neutral Sentiment: Analysts remain broadly focused on Pfizer’s valuation and earnings outlook; Erste Group raised its 2026 EPS estimate to $2.95 from $2.92, close to the approximately $2.98 consensus. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Pfizer discontinued hemophilia gene therapy BEQVEZ as the commercial market contracts and physicians demand longer-term efficacy data, removing a potential growth contributor. Gene Therapy Remains Top-of-Mind in Hemophilia
• Negative Sentiment: Pfizer agreed to a $44 million class-action settlement related to Chantix safety-disclosure claims. The financial charge is manageable relative to Pfizer’s size but highlights continuing litigation exposure. Pfizer Agreed to a $44 Million Chantix Settlement
• Negative Sentiment: Arbutus filed additional patent-enforcement lawsuits against Pfizer and BioNTech concerning lipid nanoparticle technology, creating another potential legal overhang tied to COVID vaccine intellectual property. Arbutus Reports Second-Quarter Results

Wall Street Analyst Weigh In

Several equities analysts recently commented on PFE shares. BMO Capital Markets reduced their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Pfizer in a research note on Monday, August 3rd. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.